CN107200706A - 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 - Google Patents
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 Download PDFInfo
- Publication number
- CN107200706A CN107200706A CN201610149958.6A CN201610149958A CN107200706A CN 107200706 A CN107200706 A CN 107200706A CN 201610149958 A CN201610149958 A CN 201610149958A CN 107200706 A CN107200706 A CN 107200706A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- trans
- fluoro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 103
- -1 Cyclopropylamine class compound Chemical class 0.000 title claims abstract description 72
- 229910052731 fluorine Inorganic materials 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000006467 substitution reaction Methods 0.000 title claims abstract 15
- 239000011737 fluorine Substances 0.000 title claims abstract 11
- 125000001153 fluoro group Chemical group F* 0.000 title claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 239000004472 Lysine Substances 0.000 claims abstract description 15
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims abstract description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims abstract description 14
- 239000003112 inhibitor Substances 0.000 claims abstract description 14
- 230000004048 modification Effects 0.000 claims abstract description 13
- 238000012986 modification Methods 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000005251 aryl acyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- 229910003827 NRaRb Inorganic materials 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000013985 cinnamic acid Nutrition 0.000 claims description 2
- 229930016911 cinnamic acid Natural products 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 150000002169 ethanolamines Chemical class 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 229940045996 isethionic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 claims description 2
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical class NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- 239000005864 Sulphur Substances 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 238000005576 amination reaction Methods 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- GIWQSPITLQVMSG-UHFFFAOYSA-N 1,2-dimethylimidazole Chemical class CC1=NC=CN1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 claims 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole Chemical compound CC=1C=C(C)ON=1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 claims 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 159000000013 aluminium salts Chemical class 0.000 claims 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 1
- 229910010277 boron hydride Inorganic materials 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 1
- 150000003947 ethylamines Chemical class 0.000 claims 1
- 201000005649 gangliocytoma Diseases 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000003956 methylamines Chemical class 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229960005137 succinic acid Drugs 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- LCXUCRYVFHVKRP-UHFFFAOYSA-N trimethyl-$l^{3}-iodane Chemical compound CI(C)C LCXUCRYVFHVKRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 96
- 239000003153 chemical reaction reagent Substances 0.000 description 88
- 239000002994 raw material Substances 0.000 description 87
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 28
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- STOZKUNWJBDGAF-UHFFFAOYSA-N benzyl 4-fluoro-4-formylpiperidine-1-carboxylate Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)C=O STOZKUNWJBDGAF-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- AGEZXYOZHKGVCM-PTQBSOBMSA-N bromomethylbenzene Chemical group Br[13CH2]C1=CC=CC=C1 AGEZXYOZHKGVCM-PTQBSOBMSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 6
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 6
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- IGTVZCJQBJZLEK-DLBZAZTESA-N tert-butyl 4-fluoro-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)(CN[C@@H]2C[C@H]2C3=CC=CC=C3)F IGTVZCJQBJZLEK-DLBZAZTESA-N 0.000 description 6
- KMAUOABPKMWCJQ-UHFFFAOYSA-N 1-[4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]-3-phenylpropan-1-one Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CC1)C(=O)CCc1ccccc1 KMAUOABPKMWCJQ-UHFFFAOYSA-N 0.000 description 5
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 5
- LRULVYSBRWUVGR-FCHUYYIVSA-N GSK2879552 Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCC(CN[C@H]2[C@@H](C2)C=2C=CC=CC=2)CC1 LRULVYSBRWUVGR-FCHUYYIVSA-N 0.000 description 5
- 0 NC(CC=C1C(C(C2)C2c2ccccc2)=C1)(CC1)CC*1C(OCC1CCCCC1)=O Chemical compound NC(CC=C1C(C(C2)C2c2ccccc2)=C1)(CC1)CC*1C(OCC1CCCCC1)=O 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- BBXQLXVLIQYCHN-UHFFFAOYSA-N 4-[[4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]methyl]benzoic acid Chemical compound OC(=O)c1ccc(CN2CCC(F)(CNC3CC3c3ccccc3)CC2)cc1 BBXQLXVLIQYCHN-UHFFFAOYSA-N 0.000 description 4
- WTRYSNWRQPIICD-UHFFFAOYSA-N 4-fluoro-N-methyl-4-[[(2-phenylcyclopropyl)amino]methyl]cyclohexan-1-amine Chemical compound CNC1CCC(F)(CNC2CC2c2ccccc2)CC1 WTRYSNWRQPIICD-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- BLUWYAFUQNVNRQ-LMRHVHIWSA-N Cl.FC(F)(F)C(=O)N(CC1(F)CCNCC1)[C@@H]1C[C@H]1c1ccccc1 Chemical compound Cl.FC(F)(F)C(=O)N(CC1(F)CCNCC1)[C@@H]1C[C@H]1c1ccccc1 BLUWYAFUQNVNRQ-LMRHVHIWSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- QATPZDOEVMXHQZ-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C(=O)O)C=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C(=O)O)C=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 QATPZDOEVMXHQZ-LEWJYISDSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- PEGSBTWHDGGLES-UHFFFAOYSA-N N-[(1-benzyl-4-fluoropiperidin-4-yl)methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCN(Cc2ccccc2)CC1 PEGSBTWHDGGLES-UHFFFAOYSA-N 0.000 description 4
- LEXFJWMAGCNGDX-UHFFFAOYSA-N N-[(4-fluoropiperidin-4-yl)methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCNCC1 LEXFJWMAGCNGDX-UHFFFAOYSA-N 0.000 description 4
- NGCAFPIUAYVGON-UHFFFAOYSA-N N-[[1-(3-cyclohexylpropyl)-4-fluoropiperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CCCC2CCCCC2)CC1 NGCAFPIUAYVGON-UHFFFAOYSA-N 0.000 description 4
- 150000001555 benzenes Chemical group 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- GRSPYCFNEDACGF-UHFFFAOYSA-N tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(F)(C=O)CC1 GRSPYCFNEDACGF-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- QBVRKKHXMUVJKA-UHFFFAOYSA-N 3-cyclohexyl-1-[4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]propan-1-one Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CC1)C(=O)CCC1CCCCC1 QBVRKKHXMUVJKA-UHFFFAOYSA-N 0.000 description 3
- YKXHGMBEVCIFNN-UHFFFAOYSA-N 4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]cyclohexan-1-amine Chemical compound NC1CCC(F)(CNC2CC2c2ccccc2)CC1 YKXHGMBEVCIFNN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GPWUGKZFPMOUAL-DLBZAZTESA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1)F GPWUGKZFPMOUAL-DLBZAZTESA-N 0.000 description 3
- YNJOQFBCAUCOHM-LEWJYISDSA-N C(C1=CC=CC=C1)NC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C(C1=CC=CC=C1)NC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F YNJOQFBCAUCOHM-LEWJYISDSA-N 0.000 description 3
- XCXFOENPPZVSCP-LEWJYISDSA-N C(C1=CC=CC=C1)NC(=S)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C(C1=CC=CC=C1)NC(=S)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F XCXFOENPPZVSCP-LEWJYISDSA-N 0.000 description 3
- NXHRQHMDGYFYFL-YGZJECHCSA-N C(C1=CC=CC=C1)NC1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C(C1=CC=CC=C1)NC1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F NXHRQHMDGYFYFL-YGZJECHCSA-N 0.000 description 3
- DUONQKLIJDDZJQ-FCHUYYIVSA-N C(C1=CC=CC=C1)OCN1CCC(CC1)(F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OCN1CCC(CC1)(F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 DUONQKLIJDDZJQ-FCHUYYIVSA-N 0.000 description 3
- ODFVACDSZAVYEV-RBUKOAKNSA-N C1(CCC1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C1(CCC1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F ODFVACDSZAVYEV-RBUKOAKNSA-N 0.000 description 3
- PKDLSEBVMNODFN-VQTJNVASSA-N C1(CCCC1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound C1(CCCC1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F PKDLSEBVMNODFN-VQTJNVASSA-N 0.000 description 3
- CPAZVUMGSCPNKU-VQTJNVASSA-N C1CN(CCC1(CN[C@@H]2C[C@H]2C3=CC=CC=C3)F)C(=O)OC4=CC=CC=C4 Chemical compound C1CN(CCC1(CN[C@@H]2C[C@H]2C3=CC=CC=C3)F)C(=O)OC4=CC=CC=C4 CPAZVUMGSCPNKU-VQTJNVASSA-N 0.000 description 3
- BSLBEOWOXAWIFA-RJKSWSIASA-N C1COC(CN1C(=O)OCC2=CC=CC=C2)(CN[C@@H]3C[C@H]3C4=CC=CC=C4)F Chemical compound C1COC(CN1C(=O)OCC2=CC=CC=C2)(CN[C@@H]3C[C@H]3C4=CC=CC=C4)F BSLBEOWOXAWIFA-RJKSWSIASA-N 0.000 description 3
- KORSMDPEUNOQMS-JKSUJKDBSA-N FC1(C=CN(C=C1)C(C)=O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(C=CN(C=C1)C(C)=O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 KORSMDPEUNOQMS-JKSUJKDBSA-N 0.000 description 3
- MFILRJMCIHFUGU-JSXGBRPTSA-N FC1(CC(N(CC1)C(=O)OCC1=CC=CC=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CC(N(CC1)C(=O)OCC1=CC=CC=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 MFILRJMCIHFUGU-JSXGBRPTSA-N 0.000 description 3
- PZRHIUQDVLAPMH-NIVCPKKUSA-N FC1(CCC(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCC(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 PZRHIUQDVLAPMH-NIVCPKKUSA-N 0.000 description 3
- JAAPCZCPYUAHHK-JDEYZFBPSA-N FC1(CCC(CC1)NC(C)=O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCC(CC1)NC(C)=O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 JAAPCZCPYUAHHK-JDEYZFBPSA-N 0.000 description 3
- HTURIONSSNWIJT-UTZODRGISA-N FC1(CCC(CC1)NC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCC(CC1)NC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 HTURIONSSNWIJT-UTZODRGISA-N 0.000 description 3
- GSOIXHIZXBYJQA-KSBZDLFUSA-N FC1(CCC(CC1)NS(=O)(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCC(CC1)NS(=O)(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 GSOIXHIZXBYJQA-KSBZDLFUSA-N 0.000 description 3
- SRNJJZSYEZUMDB-VQTJNVASSA-N FC1(CCN(CC1)C(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 SRNJJZSYEZUMDB-VQTJNVASSA-N 0.000 description 3
- LPAPNHVWNCLQRN-JKSUJKDBSA-N FC1(CCN(CC1)C(=O)OCC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 LPAPNHVWNCLQRN-JKSUJKDBSA-N 0.000 description 3
- UWLWGHFLVJBGLT-PZJWPPBQSA-N FC1(CCN(CC1)C(=O)OCC1=C(C=CC=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=C(C=CC=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 UWLWGHFLVJBGLT-PZJWPPBQSA-N 0.000 description 3
- VQQFQXPOGJJFGV-XZOQPEGZSA-N FC1(CCN(CC1)C(=O)OCC1=CC(=CC(=C1)OC)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC(=CC(=C1)OC)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 VQQFQXPOGJJFGV-XZOQPEGZSA-N 0.000 description 3
- XQEQRPVYFWOCQA-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC(=CC=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC(=CC=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 XQEQRPVYFWOCQA-LEWJYISDSA-N 0.000 description 3
- XYGCTWMJDRTYSL-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)Br)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)Br)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 XYGCTWMJDRTYSL-LEWJYISDSA-N 0.000 description 3
- FOVAJNVHKAXALP-BJKOFHAPSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)C(C)(C)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)C(C)(C)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FOVAJNVHKAXALP-BJKOFHAPSA-N 0.000 description 3
- UEKNEEQSPVPFNV-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)C(F)(F)F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)C(F)(F)F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 UEKNEEQSPVPFNV-LEWJYISDSA-N 0.000 description 3
- RLNHJZJGDGEJDL-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)Cl)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 RLNHJZJGDGEJDL-LEWJYISDSA-N 0.000 description 3
- PTGMLUIYOURPQM-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)F)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 PTGMLUIYOURPQM-LEWJYISDSA-N 0.000 description 3
- AWQOCDGQIINNRT-FCHUYYIVSA-N FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=C(C=C1)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 AWQOCDGQIINNRT-FCHUYYIVSA-N 0.000 description 3
- ZOAUWVODFPBWTI-LFZQMPOYSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)C(C)N[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)C(C)N[C@H]1[C@@H](C1)C1=CC=CC=C1 ZOAUWVODFPBWTI-LFZQMPOYSA-N 0.000 description 3
- SMMDNBAXWKNIKF-FCHUYYIVSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CCN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CCN[C@H]1[C@@H](C1)C1=CC=CC=C1 SMMDNBAXWKNIKF-FCHUYYIVSA-N 0.000 description 3
- KKYKKHVRQXAHMY-XZOQPEGZSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN(C(C)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN(C(C)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 KKYKKHVRQXAHMY-XZOQPEGZSA-N 0.000 description 3
- AEZWKWPEJQOCIC-FCHUYYIVSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN([C@H]1[C@@H](C1)C1=CC=CC=C1)C Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN([C@H]1[C@@H](C1)C1=CC=CC=C1)C AEZWKWPEJQOCIC-FCHUYYIVSA-N 0.000 description 3
- JVMYUJXTKVHQEC-LOSJGSFVSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC2=CC=CC=C2C=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC2=CC=CC=C2C=C1 JVMYUJXTKVHQEC-LOSJGSFVSA-N 0.000 description 3
- BMGTXUXGSMVZMB-VQTJNVASSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=NC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=NC=C1 BMGTXUXGSMVZMB-VQTJNVASSA-N 0.000 description 3
- TXVZDDXTSYPMJO-NZQKXSOJSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CNC2=CC=CC=C12 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CNC2=CC=CC=C12 TXVZDDXTSYPMJO-NZQKXSOJSA-N 0.000 description 3
- REEJTHXUYIAEIE-RBUKOAKNSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=COC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=COC=C1 REEJTHXUYIAEIE-RBUKOAKNSA-N 0.000 description 3
- FGMFGTHBSKPCNO-RBUKOAKNSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CSC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CSC=C1 FGMFGTHBSKPCNO-RBUKOAKNSA-N 0.000 description 3
- DOOFHAQZUMEGPX-JTHBVZDNSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2C=CNC2=CC=1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2C=CNC2=CC=1 DOOFHAQZUMEGPX-JTHBVZDNSA-N 0.000 description 3
- CDTQJCARSYKYSU-XZOQPEGZSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2CCCOC2=CC=1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2CCCOC2=CC=1 CDTQJCARSYKYSU-XZOQPEGZSA-N 0.000 description 3
- PJDNEWCSBIWDAF-JTHBVZDNSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2CCNC2=CC=1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2CCNC2=CC=1 PJDNEWCSBIWDAF-JTHBVZDNSA-N 0.000 description 3
- XUYZZMOPJHXSSV-IAGOWNOFSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1SC=CN=1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1SC=CN=1 XUYZZMOPJHXSSV-IAGOWNOFSA-N 0.000 description 3
- OXVZSAANYAHSSG-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1CCCCC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1CCCCC1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 OXVZSAANYAHSSG-LEWJYISDSA-N 0.000 description 3
- UBGSUKJMMHLWDP-FCHUYYIVSA-N FC1(CCN(CC1)C(=O)OCCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 UBGSUKJMMHLWDP-FCHUYYIVSA-N 0.000 description 3
- ODMJGVLIRMSRAA-DLBZAZTESA-N FC1(CCN(CC1)CCC(=O)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)CCC(=O)OC)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ODMJGVLIRMSRAA-DLBZAZTESA-N 0.000 description 3
- URTWYUOOCVGOAH-RBUKOAKNSA-N FC1(CCN(CC1)CCO)CN[C@H]1[C@@H](CCCC1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)CCO)CN[C@H]1[C@@H](CCCC1)C1=CC=CC=C1 URTWYUOOCVGOAH-RBUKOAKNSA-N 0.000 description 3
- REIBMHPXFRPYGZ-VQTJNVASSA-N FC1(CCN(CC1)S(=O)(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)S(=O)(=O)C1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 REIBMHPXFRPYGZ-VQTJNVASSA-N 0.000 description 3
- FHJJTDODGGBBHI-RBUKOAKNSA-N FC1(CN(C1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CN(C1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 FHJJTDODGGBBHI-RBUKOAKNSA-N 0.000 description 3
- HZEDEBGKCARYIR-UHFFFAOYSA-N N-[(1-benzyl-4-fluoropiperidin-4-yl)methyl]-2,2,2-trifluoro-N-(2-phenylcyclopropyl)acetamide Chemical compound FC(F)(F)C(=O)N(CC1(F)CCN(Cc2ccccc2)CC1)C1CC1c1ccccc1 HZEDEBGKCARYIR-UHFFFAOYSA-N 0.000 description 3
- CBJPQMSGXHULOG-UHFFFAOYSA-N N-[(1-fluorocyclohexyl)methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCCCC1 CBJPQMSGXHULOG-UHFFFAOYSA-N 0.000 description 3
- GQKQDRRRNMYOJG-UHFFFAOYSA-N N-[(4-fluoro-1-methylpiperidin-4-yl)methyl]-2-phenylcyclopropan-1-amine Chemical compound CN1CCC(F)(CNC2CC2c2ccccc2)CC1 GQKQDRRRNMYOJG-UHFFFAOYSA-N 0.000 description 3
- PMFXSIATAQTZAH-UHFFFAOYSA-N N-[(4-fluoro-1-phenylpiperidin-4-yl)methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CC1)c1ccccc1 PMFXSIATAQTZAH-UHFFFAOYSA-N 0.000 description 3
- JOZKVJOGRUVDEY-UHFFFAOYSA-N N-[[4-fluoro-1-(3-phenylpropyl)piperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CCCc2ccccc2)CC1 JOZKVJOGRUVDEY-UHFFFAOYSA-N 0.000 description 3
- XYWOWZOWZMZFJW-UHFFFAOYSA-N N-[[4-fluoro-1-(naphthalen-2-ylmethyl)piperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound FC1(CNC2CC2c2ccccc2)CCN(Cc2ccc3ccccc3c2)CC1 XYWOWZOWZMZFJW-UHFFFAOYSA-N 0.000 description 3
- BFBRGDFFDANMIQ-UHFFFAOYSA-N N-[[4-fluoro-1-[(4-methylsulfonylphenyl)methyl]piperidin-4-yl]methyl]-2-phenylcyclopropan-1-amine Chemical compound CS(=O)(=O)c1ccc(CN2CCC(F)(CNC3CC3c3ccccc3)CC2)cc1 BFBRGDFFDANMIQ-UHFFFAOYSA-N 0.000 description 3
- QMPZBVLKANVEFM-RBUKOAKNSA-N O1C(=CC=C1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound O1C(=CC=C1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F QMPZBVLKANVEFM-RBUKOAKNSA-N 0.000 description 3
- MOVLYZMZXQIYTE-RBUKOAKNSA-N S1C(=CC=C1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F Chemical compound S1C(=CC=C1)COC(=O)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)F MOVLYZMZXQIYTE-RBUKOAKNSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- SQNJWNSQFKPEND-UHFFFAOYSA-N benzyl 2h-pyridine-1-carboxylate Chemical compound C1C=CC=CN1C(=O)OCC1=CC=CC=C1 SQNJWNSQFKPEND-UHFFFAOYSA-N 0.000 description 3
- GZXXOJFAMSRKJW-FCHUYYIVSA-N benzyl 4-[[[(1R,2S)-2-(1-benzothiophen-5-yl)cyclopropyl]amino]methyl]-4-fluoropiperidine-1-carboxylate Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=CC2=C(C=CS2)C=1 GZXXOJFAMSRKJW-FCHUYYIVSA-N 0.000 description 3
- OVHYQOZHBHMERU-WUFINQPMSA-N benzyl 4-[[[(1R,2S)-2-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]cyclopropyl]amino]methyl]-4-fluoropiperidine-1-carboxylate Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2CCN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 OVHYQOZHBHMERU-WUFINQPMSA-N 0.000 description 3
- XVMQNWIKOLCNIM-MVJUSWEFSA-N benzyl 4-fluoro-2,6-dimethyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidine-1-carboxylate Chemical compound FC1(CC(N(C(C1)C)C(=O)OCC1=CC=CC=C1)C)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 XVMQNWIKOLCNIM-MVJUSWEFSA-N 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- ZGTHKNIBPZMMOQ-UHFFFAOYSA-N methyl 4-[[4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]methyl]benzoate Chemical compound COC(=O)c1ccc(CN2CCC(F)(CNC3CC3c3ccccc3)CC2)cc1 ZGTHKNIBPZMMOQ-UHFFFAOYSA-N 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- ITCNBUDNSGLKGZ-UHFFFAOYSA-N pyridin-4-ylmethyl 4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidine-1-carboxylate Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CC1)C(=O)OCc1ccncc1 ITCNBUDNSGLKGZ-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- UCINOBZMLCREGM-RNNUGBGQSA-N 4-n-[(1r,2s)-2-phenylcyclopropyl]cyclohexane-1,4-diamine;dihydrochloride Chemical compound Cl.Cl.C1CC(N)CCC1N[C@H]1[C@H](C=2C=CC=CC=2)C1 UCINOBZMLCREGM-RNNUGBGQSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- RFHVMLKKCSLUAS-KIRPYYLWSA-N Cl.NC1CCC(F)(CN([C@@H]2C[C@H]2c2ccccc2)C(=O)C(F)(F)F)CC1 Chemical compound Cl.NC1CCC(F)(CN([C@@H]2C[C@H]2c2ccccc2)C(=O)C(F)(F)F)CC1 RFHVMLKKCSLUAS-KIRPYYLWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- CMYNDDNZDLGSJZ-UHFFFAOYSA-N piperidin-4-ylmethyl 4-fluoro-4-[[(2-phenylcyclopropyl)amino]methyl]piperidine-1-carboxylate Chemical compound FC1(CNC2CC2c2ccccc2)CCN(CC1)C(=O)OCC1CCNCC1 CMYNDDNZDLGSJZ-UHFFFAOYSA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 2
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ITPHKCQZSPVVJB-UHFFFAOYSA-N (1-isocyanato-2-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(N=C=O)CC1=CC=CC=C1 ITPHKCQZSPVVJB-UHFFFAOYSA-N 0.000 description 1
- ZMFZVYDNZMWWQG-RFZPGFLSSA-N (1R,2R)-2-(1,3-thiazol-2-yl)cyclopropan-1-amine Chemical compound N[C@H]1[C@@H](C1)C=1SC=CN=1 ZMFZVYDNZMWWQG-RFZPGFLSSA-N 0.000 description 1
- YYVYCSYICVJZDV-VHSXEESVSA-N (1R,2S)-2-(2,3-dihydro-1-benzofuran-5-yl)cyclopropan-1-amine Chemical compound O1CCC2=C1C=CC(=C2)[C@H]1[C@@H](C1)N YYVYCSYICVJZDV-VHSXEESVSA-N 0.000 description 1
- YVLMZPMFCCHYHF-WDEREUQCSA-N (1R,2S)-2-(3,4-dihydro-2H-chromen-6-yl)cyclopropan-1-amine Chemical compound O1CCCC2=CC(=CC=C12)[C@H]1[C@@H](C1)N YVLMZPMFCCHYHF-WDEREUQCSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- WMUNIKSCJKEXKG-WCBMZHEXSA-N (1r,2s)-2-(1h-indol-3-yl)cyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CNC2=CC=CC=C12 WMUNIKSCJKEXKG-WCBMZHEXSA-N 0.000 description 1
- QVUBIQNXHRPJKK-IMTBSYHQSA-N (1r,2s)-2-(3,4-difluorophenyl)cyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=C(F)C(F)=C1 QVUBIQNXHRPJKK-IMTBSYHQSA-N 0.000 description 1
- SCLDJNREJBDLHE-VHSXEESVSA-N (1r,2s)-2-(4-methoxyphenyl)cyclopropan-1-amine Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@H](N)C1 SCLDJNREJBDLHE-VHSXEESVSA-N 0.000 description 1
- JVDFHGQPUOICBZ-VHSXEESVSA-N (1r,2s)-2-(4-methylphenyl)cyclopropan-1-amine Chemical compound C1=CC(C)=CC=C1[C@H]1[C@H](N)C1 JVDFHGQPUOICBZ-VHSXEESVSA-N 0.000 description 1
- YTAGFMUMBRBWAV-DTWKUNHWSA-N (1r,2s)-2-(4-nitrophenyl)cyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=C([N+]([O-])=O)C=C1 YTAGFMUMBRBWAV-DTWKUNHWSA-N 0.000 description 1
- WSEUISQDHJZJKD-LSDHHAIUSA-N (1r,2s)-2-(4-phenylphenyl)cyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=C(C=2C=CC=CC=2)C=C1 WSEUISQDHJZJKD-LSDHHAIUSA-N 0.000 description 1
- FLKVLOCMGKAHPS-QWHCGFSZSA-N (1r,2s)-2-naphthalen-2-ylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=C(C=CC=C2)C2=C1 FLKVLOCMGKAHPS-QWHCGFSZSA-N 0.000 description 1
- CISQJYJSJIJMML-JGVFFNPUSA-N (1r,2s)-2-pyridin-4-ylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=NC=C1 CISQJYJSJIJMML-JGVFFNPUSA-N 0.000 description 1
- LMXUPPWQKXDJNR-NKWVEPMBSA-N (1r,2s)-2-thiophen-3-ylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CSC=C1 LMXUPPWQKXDJNR-NKWVEPMBSA-N 0.000 description 1
- QJNGEXCJXPQCPA-VHSXEESVSA-N (1r,2s)-n-methyl-2-phenylcyclopropan-1-amine Chemical compound CN[C@@H]1C[C@H]1C1=CC=CC=C1 QJNGEXCJXPQCPA-VHSXEESVSA-N 0.000 description 1
- GTYFDGYGRFJTKJ-BDAKNGLRSA-N (1s,2r)-2-(4-fluorophenyl)cyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=C(F)C=C1 GTYFDGYGRFJTKJ-BDAKNGLRSA-N 0.000 description 1
- GCCKNHYFOVQZRG-UHFFFAOYSA-N (2-chlorophenyl)methyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=CC=C1Cl GCCKNHYFOVQZRG-UHFFFAOYSA-N 0.000 description 1
- GSZZXNUMOLTFSU-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methyl carbonochloridate Chemical compound COC1=CC(COC(Cl)=O)=CC(OC)=C1 GSZZXNUMOLTFSU-UHFFFAOYSA-N 0.000 description 1
- ABNOKJAUAHDRQI-UHFFFAOYSA-N (3-chlorophenyl)methyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=CC(Cl)=C1 ABNOKJAUAHDRQI-UHFFFAOYSA-N 0.000 description 1
- GRSFXTWVHXJJQN-UHFFFAOYSA-N (4-bromophenyl)methyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=C(Br)C=C1 GRSFXTWVHXJJQN-UHFFFAOYSA-N 0.000 description 1
- IJWMYYIUFNJDKN-UHFFFAOYSA-N (4-chlorophenyl)methyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=C(Cl)C=C1 IJWMYYIUFNJDKN-UHFFFAOYSA-N 0.000 description 1
- CNDKJCOMEMJVKI-UHFFFAOYSA-N (4-fluorophenyl)methyl carbonochloridate Chemical compound FC1=CC=C(COC(Cl)=O)C=C1 CNDKJCOMEMJVKI-UHFFFAOYSA-N 0.000 description 1
- BOVISBAPSYSQPI-UHFFFAOYSA-N (4-methoxyphenyl)methyl carbonochloridate Chemical compound COC1=CC=C(COC(Cl)=O)C=C1 BOVISBAPSYSQPI-UHFFFAOYSA-N 0.000 description 1
- DRUGBQDUZXAJNM-UHFFFAOYSA-N (4-tert-butylphenyl)methyl carbonochloridate Chemical compound CC(C)(C)C1=CC=C(COC(Cl)=O)C=C1 DRUGBQDUZXAJNM-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HGKPAXHJTMHWAH-UHFFFAOYSA-N 1-(bromomethyl)-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(CBr)C=C1 HGKPAXHJTMHWAH-UHFFFAOYSA-N 0.000 description 1
- HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical group C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 1
- ZBLFSFZUGHJHTC-UHFFFAOYSA-N 1-fluorocyclohexane-1-carbaldehyde Chemical compound O=CC1(F)CCCCC1 ZBLFSFZUGHJHTC-UHFFFAOYSA-N 0.000 description 1
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- DKULSTMKCYRQCP-UHFFFAOYSA-N 2-phenylethyl carbonochloridate Chemical compound ClC(=O)OCCC1=CC=CC=C1 DKULSTMKCYRQCP-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- SAJKBMWWUCUTBI-UHFFFAOYSA-N 3-bromopropylcyclohexane Chemical compound BrCCCC1CCCCC1 SAJKBMWWUCUTBI-UHFFFAOYSA-N 0.000 description 1
- JUADTOTVJUYCRQ-UHFFFAOYSA-N 3-cyclohexylpropanoyl chloride Chemical compound ClC(=O)CCC1CCCCC1 JUADTOTVJUYCRQ-UHFFFAOYSA-N 0.000 description 1
- ACXSAGHMQKTZJD-DTWKUNHWSA-N 4-[(1S,2R)-2-aminocyclopropyl]benzoic acid Chemical compound N[C@H]1[C@@H](C1)C1=CC=C(C(=O)O)C=C1 ACXSAGHMQKTZJD-DTWKUNHWSA-N 0.000 description 1
- OICUUTHFSLAPQB-VHSXEESVSA-N 4-[(1S,2R)-2-aminocyclopropyl]benzonitrile Chemical compound C(#N)C1=CC=C(C=C1)[C@H]1[C@@H](C1)N OICUUTHFSLAPQB-VHSXEESVSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- XNVQHXIHQANQJR-VHSXEESVSA-N 6-[(1S,2R)-2-aminocyclopropyl]-3,4-dihydro-1H-quinolin-2-one Chemical compound O=C1NC2=CC=C(C=C2CC1)[C@H]1[C@@H](C1)N XNVQHXIHQANQJR-VHSXEESVSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- JEBNTJVEZKAYDC-UHFFFAOYSA-N C(C)(=O)C1(CCN(CC1)C(=O)OCC1=CC=CC=C1)F Chemical compound C(C)(=O)C1(CCN(CC1)C(=O)OCC1=CC=CC=C1)F JEBNTJVEZKAYDC-UHFFFAOYSA-N 0.000 description 1
- WKBQMBQYOGTPAD-WDEREUQCSA-N C(C)(=O)C1=C(C=CC=C1)[C@H]1[C@@H](C1)N Chemical compound C(C)(=O)C1=C(C=CC=C1)[C@H]1[C@@H](C1)N WKBQMBQYOGTPAD-WDEREUQCSA-N 0.000 description 1
- SPJYBQUSPKOBPQ-UHFFFAOYSA-N C(C)(=O)NC1CCC(CC1)(C=O)F Chemical compound C(C)(=O)NC1CCC(CC1)(C=O)F SPJYBQUSPKOBPQ-UHFFFAOYSA-N 0.000 description 1
- HZEDEBGKCARYIR-LEWJYISDSA-N C(C1=CC=CC=C1)N1CCC(CC1)(F)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)N1CCC(CC1)(F)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 HZEDEBGKCARYIR-LEWJYISDSA-N 0.000 description 1
- DECVRGYPCSKKAF-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1CCC(CC1)(C=O)F Chemical compound C(C1=CC=CC=C1)NC1CCC(CC1)(C=O)F DECVRGYPCSKKAF-UHFFFAOYSA-N 0.000 description 1
- LAHXLAOPPUKCMA-JKSUJKDBSA-N C1(=CC=CC=C1)S(=O)(=O)N1CCC2=CC(=CC=C12)[C@H]1[C@@H](C1)N Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1CCC2=CC(=CC=C12)[C@H]1[C@@H](C1)N LAHXLAOPPUKCMA-JKSUJKDBSA-N 0.000 description 1
- OTSIHQLDZVGCGL-UHFFFAOYSA-N C1(=CC=CC=C1)S(=O)(=O)NC1CCC(CC1)(C=O)F Chemical compound C1(=CC=CC=C1)S(=O)(=O)NC1CCC(CC1)(C=O)F OTSIHQLDZVGCGL-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- DMSRCENKGYJVKR-UHFFFAOYSA-N CC(C)(C)OC(C1=CC=CC(COC(N(CC2)C=CC2(CN(C(C2)C2c2ccccc2)C(C(F)(F)F)=O)F)O)C=C1)=O Chemical compound CC(C)(C)OC(C1=CC=CC(COC(N(CC2)C=CC2(CN(C(C2)C2c2ccccc2)C(C(F)(F)F)=O)F)O)C=C1)=O DMSRCENKGYJVKR-UHFFFAOYSA-N 0.000 description 1
- VGYOPZUFBXSADV-UHFFFAOYSA-N CC(C)c1ccc(COC(N(CC2)CCC2(CNC(C2)C2C2C=CC=CC2)F)=[O]=C)cc1 Chemical compound CC(C)c1ccc(COC(N(CC2)CCC2(CNC(C2)C2C2C=CC=CC2)F)=[O]=C)cc1 VGYOPZUFBXSADV-UHFFFAOYSA-N 0.000 description 1
- RWQIPRWXYODIJZ-MDCZIUGASA-N CCOC(N(CC1)CCC1(CNC1([C@@H]2C1)C2c1ccccc1)F)=O Chemical compound CCOC(N(CC1)CCC1(CNC1([C@@H]2C1)C2c1ccccc1)F)=O RWQIPRWXYODIJZ-MDCZIUGASA-N 0.000 description 1
- 101150001151 CD86 gene Proteins 0.000 description 1
- PWEPARYRJMIAPT-WDEREUQCSA-N CN1C=CC2=CC(=CC=C12)[C@H]1[C@@H](C1)N Chemical compound CN1C=CC2=CC(=CC=C12)[C@H]1[C@@H](C1)N PWEPARYRJMIAPT-WDEREUQCSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- LZRFVGNFIRFMHM-UHFFFAOYSA-N ClC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C Chemical compound ClC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C LZRFVGNFIRFMHM-UHFFFAOYSA-N 0.000 description 1
- NPPZLIQLZCNZFT-UHFFFAOYSA-N ClC(=O)OCC=1C=C2C=CNC2=CC=1 Chemical compound ClC(=O)OCC=1C=C2C=CNC2=CC=1 NPPZLIQLZCNZFT-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical class OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DUWQCQUPRYDEQH-FCHUYYIVSA-N FC(F)(F)C(=O)N(CC1(F)CCN(CC1)C(=O)CCc1ccccc1)[C@@H]1C[C@H]1c1ccccc1 Chemical compound FC(F)(F)C(=O)N(CC1(F)CCN(CC1)C(=O)CCc1ccccc1)[C@@H]1C[C@H]1c1ccccc1 DUWQCQUPRYDEQH-FCHUYYIVSA-N 0.000 description 1
- GQUPTTGXFQXQBV-UHFFFAOYSA-N FC1(CC(N(C(C1)C)C(=O)OCC1=CC=CC=C1)C)C=O Chemical compound FC1(CC(N(C(C1)C)C(=O)OCC1=CC=CC=C1)C)C=O GQUPTTGXFQXQBV-UHFFFAOYSA-N 0.000 description 1
- FFQHMPAEVSEHAP-UHFFFAOYSA-N FC1(CC(N(CC1)C(=O)OCC1=CC=CC=C1)C)C=O Chemical compound FC1(CC(N(CC1)C(=O)OCC1=CC=CC=C1)C)C=O FFQHMPAEVSEHAP-UHFFFAOYSA-N 0.000 description 1
- CWWCBKDKWWPSIE-UHFFFAOYSA-N FC1(CCC(CC1)C(=O)OCC1=CC=CC=C1)C=O Chemical compound FC1(CCC(CC1)C(=O)OCC1=CC=CC=C1)C=O CWWCBKDKWWPSIE-UHFFFAOYSA-N 0.000 description 1
- LWKHEPIQPDYVKS-UHFFFAOYSA-N FC1(CCC(CC1)NC1=CC=CC=C1)C=O Chemical compound FC1(CCC(CC1)NC1=CC=CC=C1)C=O LWKHEPIQPDYVKS-UHFFFAOYSA-N 0.000 description 1
- RNBJDGYGKNXLEV-UHFFFAOYSA-N FC1(CCN(CC1)C(=O)OC1=CC=CC=C1)C=O Chemical compound FC1(CCN(CC1)C(=O)OC1=CC=CC=C1)C=O RNBJDGYGKNXLEV-UHFFFAOYSA-N 0.000 description 1
- IPXVOZXDVQUZPB-LEWJYISDSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 IPXVOZXDVQUZPB-LEWJYISDSA-N 0.000 description 1
- CEJULMWJBCHJPK-XZOQPEGZSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2C=CN(C2=CC=1)C Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=C2C=CN(C2=CC=1)C CEJULMWJBCHJPK-XZOQPEGZSA-N 0.000 description 1
- GHVPAAINJZLMSD-FCHUYYIVSA-N FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=CC2=C(CCO2)C=1 Chemical compound FC1(CCN(CC1)C(=O)OCC1=CC=CC=C1)CN[C@H]1[C@@H](C1)C=1C=CC2=C(CCO2)C=1 GHVPAAINJZLMSD-FCHUYYIVSA-N 0.000 description 1
- IVETUAAVJUGCAT-JTHBVZDNSA-N FC1(CCN(CC1)C(=O)OCC=1C=C2C=CNC2=CC=1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound FC1(CCN(CC1)C(=O)OCC=1C=C2C=CNC2=CC=1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 IVETUAAVJUGCAT-JTHBVZDNSA-N 0.000 description 1
- BBWNVERHRHLMIS-UHFFFAOYSA-N FC1(CCN(CC1)CC1=CC=C(C(=O)OC)C=C1)C=O Chemical compound FC1(CCN(CC1)CC1=CC=C(C(=O)OC)C=C1)C=O BBWNVERHRHLMIS-UHFFFAOYSA-N 0.000 description 1
- TVHDQGPZZFSIMH-UHFFFAOYSA-N FC1(CN(CCO1)C(=O)OCC1=CC=CC=C1)C=O Chemical compound FC1(CN(CCO1)C(=O)OCC1=CC=CC=C1)C=O TVHDQGPZZFSIMH-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- SDGQPMQOSARSMK-VHSXEESVSA-N N1C=CC2=CC(=CC=C12)[C@H]1[C@@H](C1)N Chemical compound N1C=CC2=CC(=CC=C12)[C@H]1[C@@H](C1)N SDGQPMQOSARSMK-VHSXEESVSA-N 0.000 description 1
- FNCMHKSOSMYKHW-VHSXEESVSA-N N1CCC2=CC(=CC=C12)[C@H]1[C@@H](C1)N Chemical compound N1CCC2=CC(=CC=C12)[C@H]1[C@@H](C1)N FNCMHKSOSMYKHW-VHSXEESVSA-N 0.000 description 1
- LBSXGNQCWVEUPK-KRIMKBQASA-N NC1CCC(CC1)(F)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 Chemical compound NC1CCC(CC1)(F)CN(C(C(F)(F)F)=O)[C@H]1[C@@H](C1)C1=CC=CC=C1 LBSXGNQCWVEUPK-KRIMKBQASA-N 0.000 description 1
- IJUVVFGCZRZNFB-UHFFFAOYSA-N NCC(CC1)(CCN1C(OCc1ccccc1)=O)F Chemical compound NCC(CC1)(CCN1C(OCc1ccccc1)=O)F IJUVVFGCZRZNFB-UHFFFAOYSA-N 0.000 description 1
- YXRIXRUBHHRCOW-NKWVEPMBSA-N O1C=C(C=C1)[C@H]1[C@@H](C1)N Chemical compound O1C=C(C=C1)[C@H]1[C@@H](C1)N YXRIXRUBHHRCOW-NKWVEPMBSA-N 0.000 description 1
- ODFVACDSZAVYEV-UHFFFAOYSA-N O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCC1CCC1 Chemical compound O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCC1CCC1 ODFVACDSZAVYEV-UHFFFAOYSA-N 0.000 description 1
- PKDLSEBVMNODFN-UHFFFAOYSA-N O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCC1CCCC1 Chemical compound O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCC1CCCC1 PKDLSEBVMNODFN-UHFFFAOYSA-N 0.000 description 1
- QMPZBVLKANVEFM-UHFFFAOYSA-N O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCc1ccc[o]1 Chemical compound O=C(N(CC1)CCC1(CNC(C1)C1c1ccccc1)F)OCc1ccc[o]1 QMPZBVLKANVEFM-UHFFFAOYSA-N 0.000 description 1
- INISDZCPOZUWSE-UHFFFAOYSA-N O=C(N(CC1)CCC1(CNC1C(Cc(cc2)cc(F)c2F)CC1)I)OCc1ccccc1 Chemical compound O=C(N(CC1)CCC1(CNC1C(Cc(cc2)cc(F)c2F)CC1)I)OCc1ccccc1 INISDZCPOZUWSE-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- ZVKSNUVXZGRELU-VHSXEESVSA-N S1C=CC2=C1C=CC(=C2)[C@H]1[C@@H](C1)N Chemical compound S1C=CC2=C1C=CC(=C2)[C@H]1[C@@H](C1)N ZVKSNUVXZGRELU-VHSXEESVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 1
- IRHXSERNHFVRLT-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methyl carbonochloridate Chemical compound FC(F)(F)C1=CC=C(COC(Cl)=O)C=C1 IRHXSERNHFVRLT-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- HUNJHHDOXCRPDL-UHFFFAOYSA-N benzyl 3-fluoro-3-formylazetidine-1-carboxylate Chemical compound FC1(CN(C1)C(=O)OCC1=CC=CC=C1)C=O HUNJHHDOXCRPDL-UHFFFAOYSA-N 0.000 description 1
- FXBIRVQWFRIPNL-UHFFFAOYSA-N benzyl 3-fluoro-3-formylpiperidine-1-carboxylate Chemical compound FC1(CN(CCC1)C(=O)OCC1=CC=CC=C1)C=O FXBIRVQWFRIPNL-UHFFFAOYSA-N 0.000 description 1
- KYXPLAWTMHZMLI-UHFFFAOYSA-N benzyl N-(4-fluoro-4-formylcyclohexyl)carbamate Chemical compound FC1(CCC(CC1)NC(OCC1=CC=CC=C1)=O)C=O KYXPLAWTMHZMLI-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VYDCMCUZQPGSKZ-UHFFFAOYSA-N cyclobutylmethyl carbonochloridate Chemical compound ClC(=O)OCC1CCC1 VYDCMCUZQPGSKZ-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- AOQONNCNKUWWRI-UHFFFAOYSA-N cyclohexylmethyl carbonochloridate Chemical compound ClC(=O)OCC1CCCCC1 AOQONNCNKUWWRI-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DDPRIBJJDYHQDB-UHFFFAOYSA-N cyclopentylmethyl carbonochloridate Chemical compound ClC(=O)OCC1CCCC1 DDPRIBJJDYHQDB-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000006565 epigenetic process Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- QBPZPLVHMVYELR-UHFFFAOYSA-N furan-2-ylmethyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=CO1 QBPZPLVHMVYELR-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- CAXRKYFRLOPCAB-UHFFFAOYSA-N propane-1,1-disulfonic acid Chemical compound CCC(S(O)(=O)=O)S(O)(=O)=O CAXRKYFRLOPCAB-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- VXSZRHMTLXXFCW-UHFFFAOYSA-N pyridin-4-ylmethyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=NC=C1 VXSZRHMTLXXFCW-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DACIJQYZZRGTPA-UHFFFAOYSA-N tert-butyl n-(4-fluoro-4-formylcyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(F)(C=O)CC1 DACIJQYZZRGTPA-UHFFFAOYSA-N 0.000 description 1
- JVCRKJVLXJXEHE-UHFFFAOYSA-N thiophen-2-ylmethyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=CS1 JVCRKJVLXJXEHE-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/24—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
- C07C209/28—Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/37—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610149958.6A CN107200706A (zh) | 2016-03-16 | 2016-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| CA3021608A CA3021608C (en) | 2016-03-16 | 2017-03-16 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
| EP17765864.8A EP3431471A4 (en) | 2016-03-16 | 2017-03-16 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION, AND USES THEREOF |
| JP2018548895A JP7605579B2 (ja) | 2016-03-16 | 2017-03-16 | フッ素置換シクロプロピルアミン系化合物並びにその製造方法、薬物組成物及び使用 |
| SG11201808017PA SG11201808017PA (en) | 2016-03-16 | 2017-03-16 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and users thereof |
| CN201780017669.3A CN108779096B (zh) | 2016-03-16 | 2017-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| PCT/CN2017/076967 WO2017157322A1 (zh) | 2016-03-16 | 2017-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| US16/085,311 US10836743B2 (en) | 2016-03-16 | 2017-03-16 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
| KR1020187029900A KR102196050B1 (ko) | 2016-03-16 | 2017-03-16 | 불소로 치환된 시클로프로필아민계 화합물 및 이의 제조 방법, 약물 조성물 및 용도 |
| RU2018136336A RU2746323C9 (ru) | 2016-03-16 | 2017-03-16 | Фторированное соединение циклопропиламина, способ получения, фармацевтическая композиция и ее использование |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610149958.6A CN107200706A (zh) | 2016-03-16 | 2016-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107200706A true CN107200706A (zh) | 2017-09-26 |
Family
ID=59850098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610149958.6A Pending CN107200706A (zh) | 2016-03-16 | 2016-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| CN201780017669.3A Active CN108779096B (zh) | 2016-03-16 | 2017-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780017669.3A Active CN108779096B (zh) | 2016-03-16 | 2017-03-16 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10836743B2 (https=) |
| EP (1) | EP3431471A4 (https=) |
| JP (1) | JP7605579B2 (https=) |
| KR (1) | KR102196050B1 (https=) |
| CN (2) | CN107200706A (https=) |
| CA (1) | CA3021608C (https=) |
| RU (1) | RU2746323C9 (https=) |
| SG (1) | SG11201808017PA (https=) |
| WO (1) | WO2017157322A1 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459476A (zh) * | 2016-06-03 | 2017-12-12 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
| CN109321940A (zh) * | 2018-11-30 | 2019-02-12 | 西南大学 | 一种酰胺的电化学氧化合成方法及其应用 |
| CN110248926A (zh) * | 2017-01-24 | 2019-09-17 | 南京明德新药研发有限公司 | Lsd1抑制剂及其制备方法和应用 |
| CN112939846A (zh) * | 2019-11-26 | 2021-06-11 | 中国科学院上海药物研究所 | 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102479789B1 (ko) | 2016-05-09 | 2022-12-22 | 주빌런트 에피코어 엘엘씨 | 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물 |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| ES3053813T3 (en) | 2019-03-20 | 2026-01-26 | Oryzon Genomics Sa | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのlsd1阻害剤の組み合わせ |
| CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Lsd1阻害薬を用いるnf1変異腫瘍の治療法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN118239883A (zh) * | 2022-12-22 | 2024-06-25 | 江苏联环药业股份有限公司 | 一类赖氨酸特异性脱甲基酶1(lsd1)抑制剂的制备方法 |
| CN118787751A (zh) * | 2023-04-12 | 2024-10-18 | 中国科学院上海药物研究所 | Lsd1抑制剂与药物联用治疗癌症的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| WO2012013728A1 (en) * | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| EA023143B1 (ru) | 2011-03-25 | 2016-04-29 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Замещенный циклопропиламин в качестве ингибитора lsd1 |
| RU2668952C2 (ru) | 2011-10-20 | 2018-10-05 | Оризон Дженомикс, С.А. | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 |
| MX356344B (es) | 2011-10-20 | 2018-05-23 | Oryzon Genomics Sa | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1. |
| MX373103B (es) * | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) * | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) * | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
-
2016
- 2016-03-16 CN CN201610149958.6A patent/CN107200706A/zh active Pending
-
2017
- 2017-03-16 SG SG11201808017PA patent/SG11201808017PA/en unknown
- 2017-03-16 JP JP2018548895A patent/JP7605579B2/ja active Active
- 2017-03-16 US US16/085,311 patent/US10836743B2/en active Active
- 2017-03-16 RU RU2018136336A patent/RU2746323C9/ru active
- 2017-03-16 CN CN201780017669.3A patent/CN108779096B/zh active Active
- 2017-03-16 CA CA3021608A patent/CA3021608C/en active Active
- 2017-03-16 KR KR1020187029900A patent/KR102196050B1/ko active Active
- 2017-03-16 EP EP17765864.8A patent/EP3431471A4/en active Pending
- 2017-03-16 WO PCT/CN2017/076967 patent/WO2017157322A1/zh not_active Ceased
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459476A (zh) * | 2016-06-03 | 2017-12-12 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
| CN107459476B (zh) * | 2016-06-03 | 2022-06-24 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
| CN110248926A (zh) * | 2017-01-24 | 2019-09-17 | 南京明德新药研发有限公司 | Lsd1抑制剂及其制备方法和应用 |
| US11433053B2 (en) | 2017-01-24 | 2022-09-06 | Medshine Discovery Inc. | LSD1 inhibitor and preparation method and application thereof |
| CN110248926B (zh) * | 2017-01-24 | 2022-12-06 | 石药集团中奇制药技术(石家庄)有限公司 | Lsd1抑制剂及其制备方法和应用 |
| CN109321940A (zh) * | 2018-11-30 | 2019-02-12 | 西南大学 | 一种酰胺的电化学氧化合成方法及其应用 |
| CN112939846A (zh) * | 2019-11-26 | 2021-06-11 | 中国科学院上海药物研究所 | 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用 |
| CN112939846B (zh) * | 2019-11-26 | 2023-12-26 | 中国科学院上海药物研究所 | 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用 |
| US12590061B2 (en) | 2019-11-26 | 2026-03-31 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019515878A (ja) | 2019-06-13 |
| RU2018136336A3 (https=) | 2020-04-16 |
| CN108779096B (zh) | 2022-07-01 |
| KR102196050B1 (ko) | 2020-12-30 |
| EP3431471A1 (en) | 2019-01-23 |
| CA3021608A1 (en) | 2017-09-21 |
| WO2017157322A1 (zh) | 2017-09-21 |
| RU2018136336A (ru) | 2020-04-16 |
| CN108779096A (zh) | 2018-11-09 |
| KR20190003941A (ko) | 2019-01-10 |
| RU2746323C2 (ru) | 2021-04-12 |
| RU2746323C9 (ru) | 2021-07-01 |
| JP7605579B2 (ja) | 2024-12-24 |
| CA3021608C (en) | 2021-09-07 |
| EP3431471A4 (en) | 2019-09-25 |
| SG11201808017PA (en) | 2018-11-29 |
| US10836743B2 (en) | 2020-11-17 |
| US20190100507A1 (en) | 2019-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107200706A (zh) | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 | |
| EP1777218B1 (en) | Process for the preparation of 4-phenoxy quinoline derivatives | |
| KR102582021B1 (ko) | Gpr139의 모듈레이터로서의 4-옥소-3,4-디히드로-1,2,3-벤조트리아진 | |
| EP1644320B1 (en) | Indane derivates as muscarinic receptor agonists | |
| CN105246887B (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| EA005819B1 (ru) | Фармацевтически активные производные сульфонамида, содержащие как липофильные, так и ионизируемые фрагменты, в качестве ингибиторов jun-протеинкиназ | |
| WO2017215464A1 (zh) | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 | |
| JP2017538676A (ja) | ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤 | |
| CN101531638A (zh) | 用作雌激素相关受体调节剂的化合物及其应用 | |
| JP6402115B2 (ja) | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 | |
| US11873292B2 (en) | Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof | |
| JP2012520246A (ja) | Kcnq2/3モジュレータとしての置換された3−アミノイソオキサゾロピリジン | |
| CN107074856A (zh) | CaMKII抑制剂及其用途 | |
| TW201038565A (en) | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators | |
| CN109336829B (zh) | 含1,2,3-三氮唑结构的芳基甲酰胺类化合物及其用途 | |
| CN114478359B (zh) | 氨基甲酸酯类trpv1拮抗/faah抑制双靶点药物及其制备方法和应用 | |
| JP4414219B2 (ja) | C−jun−n−末端キナーゼ(jnk)インヒビターとしてのアリールスルホンアミド誘導体 | |
| US20250368645A1 (en) | Beta carboline analogues as selective and biased kappa opioid receptors agonists for treating various associated pathophysiological conditions | |
| CN110483432A (zh) | 一类丙烯酸类化合物及其制备方法、药物组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170926 |
|
| WD01 | Invention patent application deemed withdrawn after publication |